Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Techglim-2
- Development stage
- Unknown
- Lead developer
- Cytech Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Techglim-2 is a branded generic formulation of glimepiride, an oral antidiabetic medication belonging to the sulfonylurea class. Developed and marketed by Cytech Pharma, it is indicated for the management of type 2 diabetes mellitus. Glimepiride acts by binding to the sulfonylurea receptor 1 (SUR1) on the surface of pancreatic beta cells, which leads to the closure of ATP-sensitive potassium (K+ATP) channels. This closure causes cell depolarization, opening of voltage-gated calcium channels, and a subsequent influx of calcium, which triggers the release of insulin. It is typically used as an adjunct to diet and exercise to improve glycemic control in patients whose blood sugar is not adequately controlled by lifestyle changes alone.
- Brand names
- Techglim-2Techglim2Techglim 2
- Other names
- glimepiride
02
Targets
SUR1 (Sulfonylurea receptor 1)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on Techglim-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Techglim-2.